Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Doseology Receives Receipt for Final Prospectus and Announces Listing on the CSE

--News Direct--

NOT FOR DISTRIBUTION IN THE UNITED STATES OR DISSEMINATION IN THE UNITED STATES

Doseology Sciences Inc. (“Doseology” or the “Company”), a diversified life sciences company, is pleased to announce that it has obtained a receipt for its final non-offering, long form prospectus dated October 29, 2021 from the British Columbia Securities Commission.

Concurrent with its prospectus filing, the Company also received approval from the Canadian Securities Exchange (the “CSE”) to list the Company’s common shares on the CSE. The approval results in the Company’s previously issued 11,885,000 Subscription Receipts (aggregate gross proceeds of $2,377,000) to be automatically converted, without further payment, into 5,942,500 units. Each unit is comprised of one common share (a “Share”) and one common share purchase warrant (a “Warrant”) with each Warrant exercisable into one Share at a price of $0.80 per Share for a period of 24 months. The Company may elect, at its option, to accelerate the expiry date of the Warrants to a date that is 30 days from the date of notice to the Warrant holders if the closing price of the Shares on the CSE is equal to or greater than $1.40 for 20 consecutive trading days.

The common shares of the Company will commence trading on the CSE on Monday, November 15, 2021 under the symbol “MOOD”.

Daniel Vice, CEO of Doseology, commented “We are thrilled to finally obtain our listing on the CSE and are appreciative of the significant efforts of our team, our advisors, and the exchange to get to the finish line”. Mr. Vice further commented, “We now look forward to significantly accelerate the development of our ambitious business plan, through organic growth, partnerships, joint ventures and acquisitions“.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The units have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the Units may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Doseology in any jurisdiction in which such offer, solicitation or sale would be unlawful.

On Behalf of the Board of Directors

Doseology Sciences Inc.

Daniel Vice

Chief Executive Officer and Director

ABOUT DOSEOLOGY (CSE: MOOD)

Doseology is a BC-based company on a mission to restore mental health through establishing psychedelic-assisted therapy clinics, building a library of intellectual property through research on psychedelic compounds, and the development and sale of its branded functional mushroom products.

The Company has filed an application with Health Canada to become a “Licensed Dealer” under the Controlled Drugs and Substances Act (Canada) which would permit the laboratory analysis of psilocybin and psilocin from mushrooms, as well as the possession, processing, sale, sending, transportation and delivery of Psychedelic Compounds.

FOR FURTHER INFORMATION CONTACT:

Investor Relations

Email: investor@doseology.com

Telephone: 236-349-0064

Website: www.doseology.com

Forward Looking Statements

This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

Contact Details

Investor Relations

+1 236-349-0064

investor@doseology.com

View source version on newsdirect.com: https://newsdirect.com/news/doseology-receives-receipt-for-final-prospectus-and-announces-listing-on-the-cse-295047757

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.